2009
London, UK, 18 December 2009 BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that it has licensed exclusive worldwide rights to Allergan to develop products for diseases...
London, UK, 05 November 2009 Strong financial and operating performance – realising benefits of Protherics acquisition BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces...
London, UK, 24 September 2009 BTG plc (LSE: BGC), the specialty pharmaceuticals company, notes today’s announcement by Genzyme Corporation that its randomised Phase III clinical trial...
London, UK, 28 August 2009 BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces the sale of its HySolv™ drug delivery technology to Novartis Pharma AG for an initial...
London, UK, 17 August 2009 BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) has received authorisation for a Clinical Trial...
London, UK, 29 July 2009 BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that its partner AstraZeneca has confirmed its intention to progress CytoFab™, an...
London, UK, 15 July 2009 BTG plc (LSE: BGC), the specialty pharmaceuticals company, today publishes its Annual General Meeting (AGM) and Interim Management Statement for the period from 1 April...
London, UK, 14 May 2009 Strong underlying results and robust cash positionIntegration of Protherics on track BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces its...
London, UK, 02 April 2009 On track to achieve planned cost savings from integration of Protherics Portfolio review completed Board and Management changes announced BTG plc (LSE: BGC), the...
London, UK, 22 January 2009 BTG plc (LSE: BGC), the specialty pharmaceuticals company, today publishes an interim management statement for the period from 1 October 2008 to 21 January. On 12...